Natera, Inc. (NASDAQ:NTRA) Insider Sells $809,294.22 in Stock

Natera, Inc. (NASDAQ:NTRA) insider Solomon Moshkevich sold 4,858 shares of Natera stock in a transaction dated Monday, December 9th. The stock was sold at an average price of $166.59, for a total value of $809,294.22. Following the sale, the insider now directly owns 114,912 shares in the company, valued at approximately $19,143,190.08. The trade was a 4.06 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website.

Solomon Moshkevich also recently made the following trade(s):

• On Monday, October 28th, Solomon Moshkevich sold 1,196 shares of Natera stock. The stock was sold at an average price of $118.21, for a total value of $141,379.16.
• On Tuesday, October 22nd, Solomon Moshkevich sold 256 shares of Natera stock. The shares were sold at an average price of $120.07, for a total value of $30,737.92.

Natera Price Performance

Shares of NASDAQ NTRA opened at $166.55 on Friday. The company has a debt-to-equity ratio of 0.33, a current ratio of 4.39 and a quick ratio of 4.23. The firm has a market capitalization of $21.99 billion, a PE ratio of -94.63 and a beta of 1.63. Natera, Inc. has a 1-year low of $57.22 and a 1-year high of $175.63. The business’s fifty day moving average price is $144.02 and its two-hundred day moving average price is $124.46.

Natera (NASDAQ:NTRA) last released its quarterly earnings data on Tuesday, November 12th. The medical research company reported ($0.26) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.31. The business had revenue of $439.80 million for the quarter, compared to analysts’ expectations of $361.43 million. Natera had a negative net margin of 14.01% and a negative return on equity of 26.23%. The company’s revenue for the quarter was up 63.9% compared to the same quarter last year. During the same quarter last year, the company earned ($0.95) EPS. On average, research analysts expect that Natera, Inc. will post -1.61 EPS for the current year.

Analyst Ratings Changes

Several research firms recently issued reports on NTRA. Robert W. Baird upped their price target on shares of Natera from $120.00 to $160.00 and gave the company an “outperform” rating in a report on Wednesday, November 13th. JPMorgan Chase & Co. upped their target price on shares of Natera from $160.00 to $200.00 and gave the company an “overweight” rating in a research note on Friday. Morgan Stanley increased their price target on shares of Natera from $132.00 to $176.00 and gave the stock an “overweight” rating in a research report on Thursday, November 14th. Piper Sandler boosted their price objective on Natera from $150.00 to $200.00 and gave the company an “overweight” rating in a report on Monday, November 18th. Finally, StockNews.com downgraded Natera from a “hold” rating to a “sell” rating in a report on Thursday, November 14th. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the company. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $147.50.

Institutional Investors Weigh In On Natera

Several large investors have recently made changes to their positions in the company. Covestor Ltd boosted its position in shares of Natera by 34.3% during the third quarter. Covestor Ltd now owns 372 shares of the medical research company’s stock worth $47,000 after buying an additional 95 shares during the period. GAMMA Investing LLC boosted its position in Natera by 32.7% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the medical research company’s stock worth $55,000 after acquiring an additional 106 shares during the period. CIBC Asset Management Inc grew its stake in shares of Natera by 3.3% in the third quarter. CIBC Asset Management Inc now owns 3,477 shares of the medical research company’s stock worth $441,000 after purchasing an additional 111 shares in the last quarter. RiverPark Advisors LLC increased its holdings in shares of Natera by 3.5% during the third quarter. RiverPark Advisors LLC now owns 3,347 shares of the medical research company’s stock valued at $425,000 after purchasing an additional 112 shares during the period. Finally, Moss Adams Wealth Advisors LLC increased its holdings in shares of Natera by 5.4% during the third quarter. Moss Adams Wealth Advisors LLC now owns 2,646 shares of the medical research company’s stock valued at $336,000 after purchasing an additional 135 shares during the period. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Company Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.